Loomis, Sayles & Company’s Axsome Therapeutics AXSM Stock Holding History

Loomis, Sayles & Company’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.4M	Sell	256,625 -58,766	-19%	-$10.2M	0.06%	118
2025 Q4	$57.6M	Sell	315,391 -14,734	-4%	-$2.06M	0.07%	93
2025 Q3	$40.1M	Buy	330,125 +52,660	+19%	+$5.93M	0.05%	136
2025 Q2	$29M	Sell	277,465 -6,705	-2%	-$710K	0.04%	179
2025 Q1	$33.1M	Sell	284,170 -5,941	-2%	-$677K	0.05%	153
2024 Q4	$24.5M	Sell	290,111 -8,475	-3%	-$779K	0.03%	223
2024 Q3	$26.8M	Buy	298,586 +29,497	+11%	+$2.57M	0.04%	219
2024 Q2	$21.7M	Sell	269,089 -10,702	-4%	-$792K	0.03%	249
2024 Q1	$22.3M	Buy	+279,791	New	+$23.5M	0.03%	244

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's AXSM Position: Q1 2026 in Review

Loomis, Sayles & Company reduced its Axsome Therapeutics (AXSM) stake by 19% in Q1 2026, selling an estimated $10.2M and leaving 256,625 shares worth $43.4M. The position accounts for 0.06% of the portfolio, ranked #118.

Loomis, Sayles & Company first reported a position in AXSM in Q1 2024 and has held it in 9 quarters since. The position peaked at $57.6M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Loomis, Sayles & Company held 256,625 shares of Axsome Therapeutics worth $43.4M as of Q1 2026.
Loomis, Sayles & Company sold 58,766 Axsome Therapeutics shares in Q1 2026, an estimated $10.2M.
Axsome Therapeutics made up 0.06% of Loomis, Sayles & Company's portfolio in Q1 2026, its #118 holding.
Loomis, Sayles & Company first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 9 quarters since.
Loomis, Sayles & Company's Axsome Therapeutics position peaked at $57.6M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.